Zealand Pharma will pay Generate Biomedicines $30 million (€27 million) upfront to discover protein drugs for obesity and ...
AATec is advancing ATL-105, a new recombinant version of alpha-1 antitrypsin for inhalation, into clinical development for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results